Table 1 Patient and tumor characteristics by type of initial radiation treatment
From: Type and dose of radiotherapy used for initial treatment of non-metastatic prostate cancer
Characteristics | Total (%)* | Patients (n)† | BT alone (%)‡ | EBRT alone (%)‡ | EBRT+BT (%)‡ | Others§(%)‡ |
|---|---|---|---|---|---|---|
Total | 100.0 | 8946 (3153) | 26.1 | 54.9 | 17.6 | 1.4 |
States (p < 0.0001)¶ | ||||||
A | 22.6 | 2025 (502) | 20.9 | 67.1 | 8.3 | 3.7 |
B | 22.7 | 2028 (906) | 21.2 | 43.9 | 34.1 | 0.8 |
C | 6.9 | 618 (174) | 30.4 | 59.1 | 9.9 | 0.6 |
D | 10.0 | 892 (586) | 30.8 | 50.8 | 16.2 | 2.2 |
E | 8.7 | 776 (251) | 25.7 | 53.0 | 21.3 | 0.0 |
F | 19.4 | 1739 (433) | 26.7 | 57.4 | 15.9 | 0.0 |
G | 9.7 | 868 (301) | 40.3 | 49.8 | 8.1 | 1.8 |
Age (y) (p < 0.0001)¶ | ||||||
20–59 | 14.7 | 1316 (499) | 27.8 | 43.5 | 27.4 | 1.3 |
60–69 | 37.7 | 3375 (1251) | 29.5 | 49.4 | 20.1 | 1.0 |
70+ | 47.6 | 4255 (1403) | 22.8 | 62.7 | 12.7 | 1.8 |
Race (p < 0.0001)¶ | ||||||
White, non-Hispanic | 72.4 | 6478 (1805) | 28.4 | 52.1 | 18.4 | 1.1 |
Black, non-Hispanic | 19.4 | 1737 (1002) | 20.1 | 61.0 | 18.1 | 0.8 |
Hispanic | 5.6 | 497 (195) | 19.7 | 65.4 | 7.0 | 7.9 |
Asians/others | 2.6 | 234 (151) | 18.8 | 63.1 | 16.1 | 2.0 |
Marital status (p = 0.2000)¶ | ||||||
Single | 22.6 | 1949 (730) | 24.0 | 58.2 | 16.9 | 0.9 |
Married | 77.4 | 6680 (2317) | 27.0 | 53.2 | 18.3 | 1.5 |
Education§ (p < 0.0001)¶ | ||||||
Not undereducated | 64.5 | 5751 (1787) | 29.0 | 51.0 | 18.7 | 1.3 |
Undereducated | 35.5 | 3166 (1357) | 21.0 | 61.7 | 15.6 | 1.7 |
Working class (p = 0.0075)¶ | ||||||
Not working class | 43.7 | 3893 (1203) | 28.2 | 50.5 | 19.8 | 1.5 |
Working class | 56.3 | 5025 (1941) | 24.5 | 58.2 | 15.9 | 1.4 |
Urbanization (p = 0.3671)¶ | ||||||
Urban | 48.5 | 4324 (1468) | 26.4 | 54.7 | 17.2 | 1.7 |
Rural | 15.4 | 1372 (525) | 23.6 | 59.7 | 15.8 | 0.9 |
Urban-Rural mix | 36.1 | 3221 (1151) | 26.8 | 52.9 | 18.9 | 1.4 |
Poverty level (p = 0.0013)¶ | ||||||
Not in poverty level | 81.1 | 7233 (2317) | 27.1 | 53.2 | 18.4 | 1.3 |
In poverty level | 18.9 | 1685 (827) | 21.7 | 61.9 | 14.4 | 2.0 |
Health insurance (p = 0.0010)¶ | ||||||
Not insured | 1.3 | 111 (50) | 11.8 | 71.2 | 12.3 | 4.7 |
Public coverage | 64.2 | 5535 (2009) | 25.1 | 57.6 | 16.4 | 0.9 |
Private coverage | 30.8 | 2660 (857) | 27.8 | 48.4 | 21.5 | 2.3 |
Insurance, NOS | 3.7 | 319 (131) | 27.0 | 46.9 | 23.9 | 2.2 |
Piccirillo comorbidity score (p = 0.2893)¶ | ||||||
None | 28.8 | 2515 (860) | 29.0 | 51.6 | 17.7 | 1.7 |
Mild | 55.2 | 4816 (1720) | 26.5 | 53.7 | 18.6 | 1.2 |
Moderate | 12.2 | 1060 (390) | 21.2 | 62.1 | 15.6 | 1.1 |
Severe | 3.8 | 327 (111) | 22.1 | 56.8 | 18.9 | 2.2 |
PSA (ng/ml) (p < 0.0001)¶ | ||||||
<10 | 72.1 | 6360 (2199) | 32.7 | 47.9 | 18.3 | 1.1 |
10–20 | 18.4 | 1620 (574) | 10.2 | 69.8 | 18.0 | 2.0 |
>20 | 9.5 | 841 (329) | 5.8 | 78.3 | 13.9 | 2.0 |
TNM Clinical T stage (p < 0.0001)¶ | ||||||
Tx-T0 | 0.5 | 49 (18) | 9.2 | 84.8 | 3.7 | 2.3 |
T1 | 64.8 | 5793 (2064) | 31.3 | 51.5 | 16.2 | 1.0 |
T2 | 31.7 | 2832 (978) | 18.2 | 58.9 | 21.0 | 1.9 |
T3-T4 | 3.0 | 268 (92) | 0.0 | 80.1 | 16.0 | 3.9 |
Gleason score (p < 0.0001)¶ | ||||||
2–6 | 56.6 | 5020 (1732) | 37.5 | 46.4 | 14.7 | 1.4 |
7 | 31.9 | 2836 (1020) | 13.0 | 62.8 | 22.9 | 1.3 |
8-10 | 11.5 | 1023 (375) | 3.9 | 75.4 | 18.6 | 2.1 |
Recurrence risk group (p < 0.0001)¶ | ||||||
LR | 41.2 | 3684 (1257) | 45.2 | 39.9 | 13.8 | 1.1 |
IR | 40.1 | 3583 (1261) | 16.1 | 60.0 | 22.5 | 1.4 |
HR | 18.8 | 1680 (635) | 5.2 | 76.8 | 15.7 | 2.3 |